Chain Drug Review - Abbott approval
Abbott Laboratories has received FDA approval for a community acquired pneumonia (CAP) indication for Biaxin XL (clarithromycin extended-release tablets). The product is a once-daily version of Biaxin and is indicated for treating mild to moderate CAP.
Related Results
Biaxin FilmtabTeva Provides Generic Biaxin XL UpdateFDA OKs Abbott's seven-day Biaxin treatmentAndrx Receives Final Approval for Generic Biaxin XL Filmtab 500mgCourt of Appeals Rules in Favor of Teva on Biaxin XL Preliminary…
COPYRIGHT 2001 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
